Connor, Clark & Lunn Investment Management Ltd. Scholar Rock Holding Corp Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$7.36 - $12.72 $169,773 - $293,412	-23,067 Reduced 29.97%	53,902 $431,000
Q4 2022 Feb 10, 2023	SELL	$7.02 - $9.76 $90,628 - $126,001	-12,910 Reduced 14.36%	76,969 $696,000
Q3 2022 Nov 10, 2022	BUY	$5.33 - $11.3 $479,055 - $1.02 Million	89,879 New	89,879 $623,000

Others Institutions Holding SRRK

# of Institutions

175

Shares Held

75.6M

Call Options Held

585K

Put Options Held

862K

Siren, L.L.C. New York, NY

11.3M
Shares

$474 Million
4.51% of portfolio
Price T Rowe Associates Inc Baltimore, MD

8.65M
Shares

$364 Million
0.01% of portfolio
Samsara Bio Capital, LLC Palo Alto, CA

6.79M
Shares

$286 Million
31.52% of portfolio
Black Rock Inc. New York, NY

5.66M
Shares

$238 Million
0.0% of portfolio
Redmile Group, LLC San Francisco, CA

5.24M
Shares

$221 Million
2.74% of portfolio

View Full List

About Scholar Rock Holding Corp

Ticker SRRK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,640,600
Market Cap $2.17B
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...

More about SRRK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account